Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone after prior atezolizumab plus bevacizumab in hepatocellular carcinoma
jRCT2031210045Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, lenvatinib, sorafenib and bevacizumab in hepatocellular carcinoma (HCC) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Jul 2021; status: active, not recruiting.
02
Drugs
atezolizumablenvatinibsorafenibbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031210045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210045.